ArticlePaediatric drugs2019
Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives.
Article in Paediatric drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A bibliometric and scientific knowledge map study of the drug therapies for asthma-related study from 1982 to 2021.Frontiers in pharmacology · 2022Pooled it
- Management of asthma exacerbations in the paediatric population: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2021Pooled it
- The evolution of scientific knowledge in childhood asthma over time.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Influence of genetic polymorphisms on omalizumab clinical response in pediatric severe asthma: a pilot study.Frontiers in pharmacology · 2026Article
- Age-specific efficacy of biologics in severe asthma: a pediatric perspective.Frontiers in allergy · 2026Review
- Updated therapeutics of asthma.World journal of pediatrics : WJP · 2025Article
- Clinical, functional, and laboratory course of children and adolescents with severe asthma after discontinuation of biologics.Frontiers in allergy · 2025Article
- Efficacy of omalizumab after discontinuation: a retrospective single-center observational study in children with severe asthma.Frontiers in allergy · 2025Article
- The Evolution of Scientific Knowledge in Childhood Asthma over Time: A Surprising History.Children (Basel, Switzerland) · 2024Review
- Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.Paediatric drugs · 2023Review
- Severe Asthma and Biological Therapies: Now and the Future.Journal of clinical medicine · 2023Review
- Novel Lung Growth Strategy with Biological Therapy Targeting Airway Remodeling in Childhood Bronchial Asthma.Children (Basel, Switzerland) · 2022Review
- Omalizumab for the treatment of severe allergic asthma in children: A tale of two.Clinical case reports · 2022Article
- Safety of biological therapy in children and adolescents with severe asthma during the COVID-19 pandemic: a case series.Acta bio-medica : Atenei Parmensis · 2022Article
- Type 2 inflammation in cystic fibrosis: New insights.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2022Article
- Biologic drugs in chronic spontaneous urticaria.Acta bio-medica : Atenei Parmensis · 2021Review
- Review
- Nocturnal non invasive ventilation in normocapnic cystic fibrosis patients: a pilot study.Acta bio-medica : Atenei Parmensis · 2021Article
- Clinical efficacy and safety of omalizumab in conventional treatment-resistant vernal keratoconjunctivitis: Our experience and literature review.Immunity, inflammation and disease · 2021Review
- Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: A Practical Review.Biologics : targets & therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe asthma in children remains a significant issue. It places a heavy burden on affected individuals and society as a whole in terms of high morbidity, mortality, consumption of healthcare resources, and side effects from high-dose corticosteroid therapy. New, targeted biologic therapies for asthma have emerged as effective add-on options, complementing our expanding understanding of asthma phenotypes/endotypes and the underlying immunopathology of the disease spectrum. They include omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab. Omalizumab represents the first available therapeutic option for allergic asthma in patients as young as 6 years of age. Its efficacy and safety have been established by several randomized controlled trials specifically conducted in pediatric patients, leading to its final registration > 10 years ago. Three new interleukin (IL)-5 targeted agents, mepolizumab, reslizumab, and benralizumab, have been approved for the treatment of severe eosinophilic asthma starting from 6 years of age, and varying by country. More recently, dupilumab, a targeted agent against the IL-4 receptor α-chain, was approved for patients ≥12 years of age in the United States after pivotal trials were completed. The late-stage clinical testing of these targeted agents has mostly involved patients aged 12 years and up, and the application of those data to younger children can be inappropriate and carry risk. The efficacy and safety of these newer biologics in children should be supported by adequate research within this targeted age group. In this review, we will present the most recent evidence on these five biological therapies for severe asthma and will discuss dosage and administration, their efficacy, safety, and future prospects, with a focus on the pediatric age group, defined as age < 18 years.
Indexed as
Identifiers
31325115What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.